Subscribe To Our Free Newsletter |
Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growth
Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore.